These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 21732357

  • 1. Inhibitory regulation of osteoclast differentiation by interleukin-3 via regulation of c-Fos and Id protein expression.
    Oh J, Lee MS, Yeon JT, Choi SW, Kim HS, Shim H, Lee SY, Youn BS, Yokota Y, Kim JH, Kwak HB.
    J Cell Physiol; 2012 May; 227(5):1851-60. PubMed ID: 21732357
    [Abstract] [Full Text] [Related]

  • 2. Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells.
    Mohamed SG, Sugiyama E, Shinoda K, Taki H, Hounoki H, Abdel-Aziz HO, Maruyama M, Kobayashi M, Ogawa H, Miyahara T.
    Bone; 2007 Oct; 41(4):592-602. PubMed ID: 17627913
    [Abstract] [Full Text] [Related]

  • 3. The mechanism of osteoclast differentiation induced by IL-1.
    Kim JH, Jin HM, Kim K, Song I, Youn BU, Matsuo K, Kim N.
    J Immunol; 2009 Aug 01; 183(3):1862-70. PubMed ID: 19587010
    [Abstract] [Full Text] [Related]

  • 4. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
    Lee JH, Jin H, Shim HE, Kim HN, Ha H, Lee ZH.
    Mol Pharmacol; 2010 Jan 01; 77(1):17-25. PubMed ID: 19828731
    [Abstract] [Full Text] [Related]

  • 5. Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL.
    Kim HN, Ha H, Lee JH, Jung K, Yang D, Woo KM, Lee ZH.
    Eur J Pharmacol; 2009 Nov 25; 623(1-3):22-9. PubMed ID: 19766111
    [Abstract] [Full Text] [Related]

  • 6. Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.
    Kamel Mohamed SG, Sugiyama E, Shinoda K, Hounoki H, Taki H, Maruyama M, Miyahara T, Kobayashi M.
    Biochem Biophys Res Commun; 2005 Apr 15; 329(3):839-45. PubMed ID: 15752732
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of osteoclast differentiation and bone resorption by rotenone, through down-regulation of RANKL-induced c-Fos and NFATc1 expression.
    Kwak HB, Lee BK, Oh J, Yeon JT, Choi SW, Cho HJ, Lee MS, Kim JJ, Bae JM, Kim SH, Kim HS.
    Bone; 2010 Mar 15; 46(3):724-31. PubMed ID: 19900598
    [Abstract] [Full Text] [Related]

  • 8. Induction of DC-STAMP by alternative activation and downstream signaling mechanisms.
    Yagi M, Ninomiya K, Fujita N, Suzuki T, Iwasaki R, Morita K, Hosogane N, Matsuo K, Toyama Y, Suda T, Miyamoto T.
    J Bone Miner Res; 2007 Jul 15; 22(7):992-1001. PubMed ID: 17402846
    [Abstract] [Full Text] [Related]

  • 9. Tanshinone IIA inhibits osteoclast differentiation through down-regulation of c-Fos and NFATc1.
    Kwak HB, Yang D, Ha H, Lee JH, Kim HN, Woo ER, Lee S, Kim HH, Lee ZH.
    Exp Mol Med; 2006 Jun 30; 38(3):256-64. PubMed ID: 16819284
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. 9-Hydroxy-6,7-dimethoxydalbergiquinol inhibits osteoclast differentiation through down-regulation of Akt, c-Fos and NFATc1.
    Kim JY, Kim JY, Cheon YH, Kwak SC, Baek JM, Kim YC, Yoon KH, Oh J, Lee MS.
    Int Immunopharmacol; 2014 May 30; 20(1):213-20. PubMed ID: 24630975
    [Abstract] [Full Text] [Related]

  • 12. Biselyngbyaside, isolated from marine cyanobacteria, inhibits osteoclastogenesis and induces apoptosis in mature osteoclasts.
    Yonezawa T, Mase N, Sasaki H, Teruya T, Hasegawa S, Cha BY, Yagasaki K, Suenaga K, Nagai K, Woo JT.
    J Cell Biochem; 2012 Feb 30; 113(2):440-8. PubMed ID: 21678460
    [Abstract] [Full Text] [Related]

  • 13. The 4-1BB ligand and 4-1BB expressed on osteoclast precursors enhance RANKL-induced osteoclastogenesis via bi-directional signaling.
    Yang J, Park OJ, Lee YJ, Jung HM, Woo KM, Choi Y.
    Eur J Immunol; 2008 Jun 30; 38(6):1598-609. PubMed ID: 18421790
    [Abstract] [Full Text] [Related]

  • 14. MS-275, a benzamide histone deacetylase inhibitor, prevents osteoclastogenesis by down-regulating c-Fos expression and suppresses bone loss in mice.
    Kim HN, Lee JH, Jin WJ, Ko S, Jung K, Ha H, Lee ZH.
    Eur J Pharmacol; 2012 Sep 15; 691(1-3):69-76. PubMed ID: 22846626
    [Abstract] [Full Text] [Related]

  • 15. Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells.
    Fujisaki K, Tanabe N, Suzuki N, Kawato T, Takeichi O, Tsuzukibashi O, Makimura M, Ito K, Maeno M.
    Life Sci; 2007 Mar 13; 80(14):1311-8. PubMed ID: 17306833
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Apolipoprotein E inhibits osteoclast differentiation via regulation of c-Fos, NFATc1 and NF-κB.
    Kim WS, Kim HJ, Lee ZH, Lee Y, Kim HH.
    Exp Cell Res; 2013 Feb 15; 319(4):436-46. PubMed ID: 23246654
    [Abstract] [Full Text] [Related]

  • 19. Ginsenoside Rh2 inhibits osteoclastogenesis through down-regulation of NF-κB, NFATc1 and c-Fos.
    He L, Lee J, Jang JH, Lee SH, Nan MH, Oh BC, Lee SG, Kim HH, Soung NK, Ahn JS, Kim BY.
    Bone; 2012 Jun 15; 50(6):1207-13. PubMed ID: 22484180
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.